Novel unit B cryptophycin analogues as payloads for targeted therapy

Scholarly Works

• Lee, H.; Nihan, K.; Kwon, Y. R. Cyanobacterial Peptides in Anticancer Therapy: A Comprehensive Review of Mechanisms, Clinical Advances, and Biotechnological Innovation. Marine drugs 2025, 23, 233. doi:10.3390/md23060233
• Schachtsiek, T.; Voss, J.; Hamsen, M.; Neumann, B.; Stammler, H.-G.; Sewald, N. Cryptophycin unit B analogues. Beilstein journal of organic chemistry 2025, 21, 526–532. doi:10.3762/bjoc.21.40
• Dessin, C.; Schachtsiek, T.; Voss, J.; Abel, A.-C.; Neumann, B.; Stammler, H.-G.; Prota, A. E.; Sewald, N. Highly Cytotoxic Cryptophycin Derivatives with Modification in Unit D for Conjugation. Angewandte Chemie (International ed. in English) 2024, 63, e202416210. doi:10.1002/anie.202416210
• Dessin, C.; Schachtsiek, T.; Voss, J.; Abel, A.; Neumann, B.; Stammler, H.; Prota, A. E.; Sewald, N. Hochgradig cytotoxische Cryptophycine mit modifiziertem Fragment D zur Konjugation. Angewandte Chemie 2024, 136. doi:10.1002/ange.202416210
• Hofmann, S.; Dombrowsky, C.; Happel, D.; Dessin, C.; Cermjani, E.; Cica, M.; Avrutina, O.; Sewald, N.; Neumann, H.; Kolmar, H. Conditional Cell Penetration of Masked CPPs by an ADEPT-like Approach. ACS chemical biology 2024, 19, 1320–1329. doi:10.1021/acschembio.4c00149
• Paulus, J.; Sewald, N. Small molecule- and peptide-drug conjugates addressing integrins: A story of targeted cancer treatment. Journal of peptide science : an official publication of the European Peptide Society 2024, 30, e3561. doi:10.1002/psc.3561
• Moschona, F.; Savvopoulou, I.; Tsitopoulou, M.; Tataraki, D.; Rassias, G. A. Epoxide Syntheses and Ring-Opening Reactions in Drug Development. Catalysts 2020, 10, 1117. doi:10.3390/catal10101117
• Thuan, N. H.; An, T. T.; Shrestha, A.; Canh, N. X.; Sohng, J. K.; Dhakal, D. Recent Advances in Exploration and Biotechnological Production of Bioactive Compounds in Three Cyanobacterial Genera: Nostoc, Lyngbya, and Microcystis. Frontiers in chemistry 2019, 7, 604. doi:10.3389/fchem.2019.00604
• Borbély, A.; Figueras, E.; Martins, A.; Bodero, L.; Dias, A. R. M.; Rivas, P. L.; Pina, A.; Arosio, D.; Gallinari, P.; Frese, M.; Steinkühler, C.; Gennari, C.; Piarulli, U.; Sewald, N. Conjugates of Cryptophycin and RGD or isoDGR Peptidomimetics for Targeted Drug Delivery. ChemistryOpen 2019, 8, 737–742. doi:10.1002/open.201900110
• Figueras, E.; Martins, A.; Borbély, A.; Le Joncour, V.; Cordella, P.; Perego, R.; Modena, D.; Pagani, P.; Esposito, S.; Auciello, G.; Frese, M.; Gallinari, P.; Laakkonen, P.; Steinkühler, C.; Sewald, N. Octreotide Conjugates for Tumor Targeting and Imaging. Pharmaceutics 2019, 11, 220. doi:10.3390/pharmaceutics11050220
• Borbély, A.; Figueras, E.; Martins, A.; Esposito, S.; Auciello, G.; Monteagudo, E.; Di Marco, A.; Summa, V.; Cordella, P.; Perego, R.; Kemker, I.; Frese, M.; Gallinari, P.; Steinkühler, C.; Sewald, N. Synthesis and Biological Evaluation of RGD–Cryptophycin Conjugates for Targeted Drug Delivery. Pharmaceutics 2019, 11, 151. doi:10.3390/pharmaceutics11040151
• Cazzamalli, S.; Figueras, E.; Pethő, L.; Borbély, A.; Steinkühler, C.; Neri, D.; Sewald, N. In Vivo Antitumor Activity of a Novel Acetazolamide-Cryptophycin Conjugate for the Treatment of Renal Cell Carcinomas. ACS omega 2018, 3, 14726–14731. doi:10.1021/acsomega.8b02350

Explore citations to this article at